BANK VONTOBEL/CALL/GILEAD SCIENCES/74/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 18:51:23 05/06/2024 BST | ||
| 0.058 EUR | +9.43% |
|
| 1 month | -40.45% | ||
| 3 months | -86.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/06/24 | 0.058 | +9.43% |
| 04/06/24 | 0.053 | +8.16% |
| 03/06/24 | 0.049 | +6.52% |
| 31/05/24 | 0.046 | -23.33% |
| 30/05/24 | 0.06 | +30.43% |
Delayed Quote Deutsche Boerse AG
Last update June 05, 2024 at 06:51 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VM3Q54 |
| ISIN | DE000VM3Q547 |
| Date issued | 09/10/2023 |
| Strike | 74 $ |
| Maturity | 20/09/2024 (107 Days) |
| Parity | 10 : 1 |
| Emission price | 0.8 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.53 € |
|---|---|
| Lowest since issue | 0.043 € |
| Spread | 0.01 € |
| Spread % | 15.38% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.16
USD
Average target price
82.7
USD
Spread / Average Target
+28.89%
- Stock Market
- Warrants
- Warrant
